{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:53Z","timestamp":1792785053769,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancer Research UK","award":["C14303\/A17197 and A28290"],"award-info":[{"award-number":["C14303\/A17197 and A28290"]}],"id":[{"id":"https:\/\/ror.org\/054225q67","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MC_UU_0002\/16"],"award-info":[{"award-number":["MC_UU_0002\/16"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health and Care Research","award":["NF-SI-0515-10090"],"award-info":[{"award-number":["NF-SI-0515-10090"]}],"id":[{"id":"https:\/\/ror.org\/0187kwz08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"European Research Council","award":["694620"],"award-info":[{"award-number":["694620"]}],"id":[{"id":"https:\/\/ror.org\/0472cxd90","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer is the second most common cancer globally, with rising incidence and poor prognosis following recurrence. Genomic analysis of primary breast tumours has identified subtypes with widely varying risk of relapse, highlighting the importance of tumour genomics in understanding metastasis. However, the genomic alterations associated with metastatic transformation\u2014and how they differ between genomic subtypes\u2014remain unclear due to limited sample sizes, lack of primary tumour baselines, and limited genomic coverage by panel sequencing. To address this gap, we analysed nearly 1300 whole-genome sequenced unmatched primary tumours and metastases using a unified computational pipeline. Somatic copy number profiles were classified into genomic subtypes, called the Integrative Clusters, with an improved classifier. By employing various genome-wide approaches, we identify candidate genes in regions with copy number alterations enriched or depleted in metastases, and nominate biological pathways that may contribute to metastatic disease in each genomic subtype. These subtype-specific candidates provide a framework for prioritising therapeutic hypotheses and future functional studies in metastatic breast cancer.<\/jats:p>","DOI":"10.1038\/s41598-026-60972-2","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:53:51Z","timestamp":1783781631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breast cancer genomic subtype-specific copy number alterations in metastases"],"prefix":"10.1038","volume":"16","author":[{"given":"Katherine","family":"Eason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Boursnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A. W.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suet-Feung","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Markowetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar M.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"60972_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., Jemal, A. Global Cancer Statistics","year":"2022","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., Jemal, A. Global Cancer Statistics. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21834 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"60972_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni, M. et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials i to v. JCO 34, 927\u2013935. https:\/\/doi.org\/10.1200\/JCO.2015.62.3504 (2016).","journal-title":"JCO"},{"key":"60972_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","volume":"124","author":"AI Riggio","year":"2021","unstructured":"Riggio, A. I., Varley, K. E. & Welm, A. L. The lingering mysteries of metastatic recurrence in breast cancer. Br. J. Cancer 124, 13\u201326. https:\/\/doi.org\/10.1038\/s41416-020-01161-4 (2021).","journal-title":"Br. J. Cancer"},{"key":"60972_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/A:1006285726561","volume":"56","author":"A Insa","year":"1999","unstructured":"Insa, A. et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: Analysis of 439 patients. Breast Cancer Res. Treat. 56, 67\u201378. https:\/\/doi.org\/10.1023\/A:1006285726561 (1999).","journal-title":"Breast Cancer Res. Treat."},{"key":"60972_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","volume":"567","author":"OM Rueda","year":"2019","unstructured":"Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399\u2013404. https:\/\/doi.org\/10.1038\/s41586-019-1007-8 (2019).","journal-title":"Nature"},{"key":"60972_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352. https:\/\/doi.org\/10.1038\/nature10983 (2012).","journal-title":"Nature"},{"key":"60972_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s13059-014-0431-1","volume":"15","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Genome-driven integrated classification of breast cancer validated in over 7500 samples. Genome Biol. 15, 431. https:\/\/doi.org\/10.1186\/s13059-014-0431-1 (2014).","journal-title":"Genome Biol."},{"key":"60972_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127\u20131133. https:\/\/doi.org\/10.1038\/ng.2762 (2013).","journal-title":"Nat. Genet."},{"key":"60972_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast Cancer. Nat. Rev. Dis. Primers 5, 1\u201331. https:\/\/doi.org\/10.1038\/s41572-019-0111-2 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"60972_CR10","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.celrep.2019.04.098","volume":"27","author":"L De Mattos-Arruda","year":"2019","unstructured":"De Mattos-Arruda, L. et al. The genomic and immune landscapes of lethal metastatic breast cancer. Cell Rep. 27, 2690-2708.e10. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.098 (2019).","journal-title":"Cell Rep."},{"key":"60972_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","volume":"52","author":"Z Hu","year":"2020","unstructured":"Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701\u2013708. https:\/\/doi.org\/10.1038\/s41588-020-0628-z (2020).","journal-title":"Nat. Genet."},{"key":"60972_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563-575.e11. https:\/\/doi.org\/10.1016\/j.cell.2022.01.003 (2022).","journal-title":"Cell"},{"key":"60972_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates, L. R. et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32, 169-184.e7. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.005 (2017).","journal-title":"Cancer Cell"},{"key":"60972_CR14","doi-asserted-by":"publisher","first-page":"11861","DOI":"10.1038\/s41598-024-62724-6","volume":"14","author":"CC Young","year":"2024","unstructured":"Young, C. C. et al. Development and validation of a reliable DNA copy-number-based machine learning algorithm (CopyClust) for breast cancer integrative cluster classification. Sci. Rep. 14, 11861. https:\/\/doi.org\/10.1038\/s41598-024-62724-6 (2024).","journal-title":"Sci. Rep."},{"key":"60972_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s10549-012-2398-5","volume":"137","author":"A Yamada","year":"2013","unstructured":"Yamada, A. et al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res. Treat. 137, 773\u2013782. https:\/\/doi.org\/10.1007\/s10549-012-2398-5 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"60972_CR16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994\u20131007. https:\/\/doi.org\/10.1016\/j.cell.2012.04.023 (2012).","journal-title":"Cell"},{"key":"60972_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.4161\/cc.28156","volume":"13","author":"I Mercier","year":"2014","unstructured":"Mercier, I. et al. CAPER, a novel regulator of human breast cancer progression. Cell Cycle 13, 1256\u20131264. https:\/\/doi.org\/10.4161\/cc.28156 (2014).","journal-title":"Cell Cycle"},{"key":"60972_CR18","doi-asserted-by":"publisher","first-page":"10810","DOI":"10.1038\/ncomms10810","volume":"7","author":"X Zhang","year":"2016","unstructured":"Zhang, X. et al. G9a-mediated methylation of ER links the PHF20\/MOF histone acetyltransferase complex to hormonal gene expression. Nat. Commun. 7, 10810. https:\/\/doi.org\/10.1038\/ncomms10810 (2016).","journal-title":"Nat. Commun."},{"key":"60972_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen, J. et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 5, 752\u2013767. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0849 (2015).","journal-title":"Cancer Discov."},{"key":"60972_CR20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.molcel.2009.06.030","volume":"35","author":"Y-W Zhang","year":"2009","unstructured":"Zhang, Y.-W. et al. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol. Cell 35, 442\u2013453. https:\/\/doi.org\/10.1016\/j.molcel.2009.06.030 (2009).","journal-title":"Mol. Cell"},{"key":"60972_CR21","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1073\/pnas.111137198","volume":"98","author":"A Liu","year":"2001","unstructured":"Liu, A., Cerniglia, G. J., Bernhard, E. J. & Prendergast, G. C. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc. Natl. Acad. Sci. 98, 6192\u20136197. https:\/\/doi.org\/10.1073\/pnas.111137198 (2001).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"60972_CR22","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdy216","volume":"29","author":"M Diossy","year":"2018","unstructured":"Diossy, M. et al. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann. Oncol. 29, 1948\u20131954. https:\/\/doi.org\/10.1093\/annonc\/mdy216 (2018).","journal-title":"Ann. Oncol."},{"key":"60972_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.27838","volume":"62","author":"SY Lim","year":"2015","unstructured":"Lim, S. Y. et al. Cd11b+ myeloid cells support hepatic metastasis through down-regulation of angiopoietin-like 7 in cancer cells. Hepatology 62, 521. https:\/\/doi.org\/10.1002\/hep.27838 (2015).","journal-title":"Hepatology"},{"key":"60972_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1101\/gad.14.3.289","volume":"14","author":"SY Shieh","year":"2000","unstructured":"Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y. & Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate P53 at multiple DNA damage-inducible sites. Genes Dev. 14, 289\u2013300 (2000).","journal-title":"Genes Dev."},{"key":"60972_CR25","doi-asserted-by":"publisher","first-page":"44475","DOI":"10.1074\/jbc.M403722200","volume":"279","author":"M-S Dai","year":"2004","unstructured":"Dai, M.-S. & Lu, H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279, 44475\u201344482. https:\/\/doi.org\/10.1074\/jbc.M403722200 (2004).","journal-title":"J. Biol. Chem."},{"key":"60972_CR26","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1128\/MCB.24.13.5835-5843.2004","volume":"24","author":"D Danovi","year":"2004","unstructured":"Danovi, D. et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting P53 tumor suppressor activity. Mol. Cell. Biol. 24, 5835\u20135843. https:\/\/doi.org\/10.1128\/MCB.24.13.5835-5843.2004 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"60972_CR27","doi-asserted-by":"publisher","first-page":"eadg4521","DOI":"10.1126\/science.adg4521","volume":"381","author":"V Girish","year":"2023","unstructured":"Girish, V. et al. Oncogene-like addiction to aneuploidy in human cancers. Science 381, eadg4521. https:\/\/doi.org\/10.1126\/science.adg4521 (2023).","journal-title":"Science"},{"key":"60972_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171356","volume":"12","author":"T Takeda","year":"2017","unstructured":"Takeda, T. et al. Yes1 signaling mediates the resistance to trastuzumab\/lapatinib in breast cancer. PLOS ONE 12, e0171356. https:\/\/doi.org\/10.1371\/journal.pone.0171356 (2017).","journal-title":"PLOS ONE"},{"key":"60972_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12885-019-6496-1","volume":"20","author":"Z Cierna","year":"2020","unstructured":"Cierna, Z. et al. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. BMC Cancer 20, 17. https:\/\/doi.org\/10.1186\/s12885-019-6496-1 (2020).","journal-title":"BMC Cancer"},{"key":"60972_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0960-9822(99)80118-3","volume":"9","author":"B K\u00f6berle","year":"1999","unstructured":"K\u00f6berle, B., Masters, J. R. W., Hartley, J. A. & Wood, R. D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 9, 273\u2013278. https:\/\/doi.org\/10.1016\/S0960-9822(99)80118-3 (1999).","journal-title":"Curr. Biol."},{"key":"60972_CR31","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/carcin\/bgs142","volume":"33","author":"Y Liu","year":"2012","unstructured":"Liu, Y., Bernauer, A. M., Yingling, C. M. & Belinsky, S. A. HIF1 regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 33, 1187\u20131192. https:\/\/doi.org\/10.1093\/carcin\/bgs142 (2012).","journal-title":"Carcinogenesis"},{"key":"60972_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01197","author":"N Pajuelo-Lozano","year":"2018","unstructured":"Pajuelo-Lozano, N. et al. XPA, XPC, and XPD modulate sensitivity in gastric cisplatin resistance cancer cells. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.01197 (2018).","journal-title":"Front. Pharmacol."},{"key":"60972_CR33","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1101\/gad.225680.113","volume":"27","author":"MC Jaramillo","year":"2013","unstructured":"Jaramillo, M. C. & Zhang, D. D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27, 2179\u20132191. https:\/\/doi.org\/10.1101\/gad.225680.113 (2013).","journal-title":"Genes Dev."},{"key":"60972_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0092-8674(00)80521-8","volume":"90","author":"W Gu","year":"1997","unstructured":"Gu, W. & Roeder, R. G. Activation of P53 sequence-specific DNA binding by acetylation of the P53 C-terminal domain. Cell 90, 595\u2013606. https:\/\/doi.org\/10.1016\/S0092-8674(00)80521-8 (1997).","journal-title":"Cell"},{"key":"60972_CR35","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1126\/science.287.5459.1824","volume":"287","author":"A Hirao","year":"2000","unstructured":"Hirao, A. et al. DNA damage-induced activation of P53 by the checkpoint kinase Chk2. Science 287, 1824\u20131827. https:\/\/doi.org\/10.1126\/science.287.5459.1824 (2000).","journal-title":"Science"},{"key":"60972_CR36","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1038\/oncsis.2013.11","volume":"2","author":"TP Molitor","year":"2013","unstructured":"Molitor, T. P. & Traktman, P. Molecular genetic analysis of VRK1 in mammary epithelial cells: Depletion slows proliferation in vitro and tumor growth and metastasis in vivo. Oncogenesis 2, e48\u2013e48. https:\/\/doi.org\/10.1038\/oncsis.2013.11 (2013).","journal-title":"Oncogenesis"},{"key":"60972_CR37","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.18632\/oncotarget.1678","volume":"5","author":"M Salzano","year":"2014","unstructured":"Salzano, M. et al. Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response. Oncotarget 5, 1770\u20131778. https:\/\/doi.org\/10.18632\/oncotarget.1678 (2014).","journal-title":"Oncotarget"},{"key":"60972_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/15592294.2015.1028708","volume":"10","author":"M Salzano","year":"2015","unstructured":"Salzano, M., Sanz-Garc\u00eda, M., Monsalve, D. M., Moura, D. S. & Lazo, P. A. VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage. Epigenetics 10, 373\u2013383. https:\/\/doi.org\/10.1080\/15592294.2015.1028708 (2015).","journal-title":"Epigenetics"},{"key":"60972_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100329","volume":"296","author":"M Gagnon","year":"2021","unstructured":"Gagnon, M. et al. Potentiation of B2 receptor signaling by AltB2R, a newly identified alternative protein encoded in the human bradykinin B2 receptor gene. J. Biol. Chem. 296, 100329. https:\/\/doi.org\/10.1016\/j.jbc.2021.100329 (2021).","journal-title":"J. Biol. Chem."},{"key":"60972_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-012-2229-8","volume":"136","author":"MA Quintayo","year":"2012","unstructured":"Quintayo, M. A. et al. GSK3 and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Res. Treat. 136, 161\u2013168. https:\/\/doi.org\/10.1007\/s10549-012-2229-8 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"60972_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.canlet.2008.05.045","volume":"273","author":"J Luo","year":"2009","unstructured":"Luo, J. Glycogen synthase kinase 3$$\\beta$$ (GSK3) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273, 194\u2013200. https:\/\/doi.org\/10.1016\/j.canlet.2008.05.045 (2009).","journal-title":"Cancer Lett."},{"key":"60972_CR42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10549-010-1058-x","volume":"128","author":"G P\u00e9rez-Tenorio","year":"2011","unstructured":"P\u00e9rez-Tenorio, G. et al. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res. Treat. 128, 713\u2013723. https:\/\/doi.org\/10.1007\/s10549-010-1058-x (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"60972_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1172\/JCI93815","volume":"128","author":"P Mishra","year":"2018","unstructured":"Mishra, P. et al. ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming. J. Clin. Invest. 128, 323\u2013340. https:\/\/doi.org\/10.1172\/JCI93815 (2018).","journal-title":"J. Clin. Invest."},{"key":"60972_CR44","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s10555-023-10118-x","volume":"42","author":"C Prunier","year":"2023","unstructured":"Prunier, C., Chavrier, P. & Boissan, M. Mechanisms of action of NME metastasis suppressors\u2014A family affair. Cancer Metastasis Rev. 42, 1155\u20131167. https:\/\/doi.org\/10.1007\/s10555-023-10118-x (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"60972_CR45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41586-023-06266-3","volume":"619","author":"J Shih","year":"2023","unstructured":"Shih, J. et al. Cancer aneuploidies are shaped primarily by effects on tumour fitness. Nature 619, 793\u2013800. https:\/\/doi.org\/10.1038\/s41586-023-06266-3 (2023).","journal-title":"Nature"},{"key":"60972_CR46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/emboj.2011.490","volume":"31","author":"R Brough","year":"2012","unstructured":"Brough, R. et al. APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. EMBO J. 31, 1160\u20131176. https:\/\/doi.org\/10.1038\/emboj.2011.490 (2012).","journal-title":"EMBO J."},{"key":"60972_CR47","doi-asserted-by":"publisher","first-page":"eabl9794","DOI":"10.1126\/sciadv.abl9794","volume":"8","author":"C Miao","year":"2022","unstructured":"Miao, C. et al. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Sci. Adv. 8, eabl9794. https:\/\/doi.org\/10.1126\/sciadv.abl9794 (2022).","journal-title":"Sci. Adv."},{"key":"60972_CR48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1126\/science.1130512","volume":"314","author":"H Huang","year":"2006","unstructured":"Huang, H., Regan, K. M., Lou, Z., Chen, J. & Tindall, D. J. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314, 294\u2013297. https:\/\/doi.org\/10.1126\/science.1130512 (2006).","journal-title":"Science"},{"key":"60972_CR49","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016600","volume":"7","author":"R Prakash","year":"2015","unstructured":"Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous recombination and human health: The roles of BRCA1, BRCA2, and associated proteins. Cold Spring. Harb. Perspect. Biol. 7, a016600. https:\/\/doi.org\/10.1101\/cshperspect.a016600 (2015).","journal-title":"Cold Spring. Harb. Perspect. Biol."},{"key":"60972_CR50","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek, D. et al. The cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158\u20132172. https:\/\/doi.org\/10.1101\/gad.16962311 (2011).","journal-title":"Genes Dev."},{"key":"60972_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500447","volume":"1","author":"C Kadoch","year":"2015","unstructured":"Kadoch, C. & Crabtree, G. R. Mammalian SWI\/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci. Adv. 1, e1500447. https:\/\/doi.org\/10.1126\/sciadv.1500447 (2015).","journal-title":"Sci. Adv."},{"key":"60972_CR52","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.4161\/cc.6.13.4336","volume":"6","author":"KD Hester","year":"2007","unstructured":"Hester, K. D. et al. Differential repression of C-Myc and Cdc2 gene expression by ERF and PE-1\/METS. Cell Cycle 6, 1594\u20131604. https:\/\/doi.org\/10.4161\/cc.6.13.4336 (2007).","journal-title":"Cell Cycle"},{"key":"60972_CR53","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.celrep.2017.01.031","volume":"18","author":"B Wang","year":"2017","unstructured":"Wang, B. et al. ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition. Cell Rep. 18, 1543\u20131557. https:\/\/doi.org\/10.1016\/j.celrep.2017.01.031 (2017).","journal-title":"Cell Rep."},{"key":"60972_CR54","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1073\/pnas.0711711105","volume":"105","author":"O Klezovitch","year":"2008","unstructured":"Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. 105, 2105\u20132110. https:\/\/doi.org\/10.1073\/pnas.0711711105 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"60972_CR55","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nature01803","volume":"424","author":"E Trompouki","year":"2003","unstructured":"Trompouki, E. et al. CYLD Is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793\u2013796. https:\/\/doi.org\/10.1038\/nature01803 (2003).","journal-title":"Nature"},{"key":"60972_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s10020-022-00439-y","volume":"28","author":"A Erol","year":"2022","unstructured":"Erol, A. IKK-mediated CYLD phosphorylation and cellular redox activity. Mol. Med. 28, 14. https:\/\/doi.org\/10.1186\/s10020-022-00439-y (2022).","journal-title":"Mol. Med."},{"key":"60972_CR57","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164\u20131177. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0369 (2015).","journal-title":"Cancer Discov."},{"key":"60972_CR58","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","volume":"11","author":"P Aftimos","year":"2021","unstructured":"Aftimos, P. et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the breast international group (BIG) molecular screening initiative. Cancer Discov. 11, 2796\u20132811. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1647 (2021).","journal-title":"Cancer Discov."},{"key":"60972_CR59","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ejhg.2009.230","volume":"18","author":"AB Pop\u0142awski","year":"2010","unstructured":"Pop\u0142awski, A. B. et al. Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression. Eur. J. Hum. Genet. 18, 560\u2013568. https:\/\/doi.org\/10.1038\/ejhg.2009.230 (2010).","journal-title":"Eur. J. Hum. Genet."},{"key":"60972_CR60","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41586-024-08377-x","volume":"638","author":"KE Houlahan","year":"2025","unstructured":"Houlahan, K. E. et al. Complex rearrangements fuel ER+ and HER2+ breast tumours. Nature 638, 510\u2013518. https:\/\/doi.org\/10.1038\/s41586-024-08377-x (2025).","journal-title":"Nature"},{"key":"60972_CR61","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41586-025-09812-3","volume":"649","author":"R Kim","year":"2026","unstructured":"Kim, R. et al. Whole-genome landscapes of 1364 breast cancers. Nature 649, 1282\u20131291. https:\/\/doi.org\/10.1038\/s41586-025-09812-3 (2026).","journal-title":"Nature"},{"key":"60972_CR62","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","volume":"601","author":"S-J Sammut","year":"2022","unstructured":"Sammut, S.-J. et al. Multi-omic machine learning predictor of breast cancer therapy response. Nature 601, 623\u2013629. https:\/\/doi.org\/10.1038\/s41586-021-04278-5 (2022).","journal-title":"Nature"},{"key":"60972_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354. https:\/\/doi.org\/10.1038\/nature17676 (2016).","journal-title":"Nature"},{"key":"60972_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210\u2013216. https:\/\/doi.org\/10.1038\/s41586-019-1689-y (2019).","journal-title":"Nature"},{"key":"60972_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635 (2013).","journal-title":"Bioinformatics"},{"key":"60972_CR66","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419. https:\/\/doi.org\/10.1038\/nmeth.4197 (2017).","journal-title":"Nat. Methods"},{"key":"60972_CR67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616 (2010).","journal-title":"Bioinformatics"},{"key":"60972_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47. https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res."},{"key":"60972_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku864","volume":"42","author":"JT Leek","year":"2014","unstructured":"Leek, J. T. Svaseq: Removing batch effects and other unwanted noise from sequencing data. Nucleic Acids Res. 42, e161. https:\/\/doi.org\/10.1093\/nar\/gku864 (2014).","journal-title":"Nucleic Acids Res."},{"key":"60972_CR70","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","volume":"32","author":"DMA Gendoo","year":"2016","unstructured":"Gendoo, D. M. A. et al. Genefu: An R\/bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics 32, 1097\u20131099. https:\/\/doi.org\/10.1093\/bioinformatics\/btv693 (2016).","journal-title":"Bioinformatics"},{"key":"60972_CR71","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2658 human cancer genomes. Cell 184, 2239-2254.e39. https:\/\/doi.org\/10.1016\/j.cell.2021.03.009 (2021).","journal-title":"Cell"},{"key":"60972_CR72","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/bioinformatics\/btw163","volume":"32","author":"E Roller","year":"2016","unstructured":"Roller, E., Ivakhno, S., Lee, S., Royce, T. & Tanner, S. Canvas: Versatile and scalable detection of copy number variants. Bioinformatics 32, 2375\u20132377. https:\/\/doi.org\/10.1093\/bioinformatics\/btw163 (2016).","journal-title":"Bioinformatics"},{"key":"60972_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/computation9020017","volume":"9","author":"H Saker","year":"2021","unstructured":"Saker, H. et al. Weighted consensus segmentations. Computation 9, 17. https:\/\/doi.org\/10.3390\/computation9020017 (2021).","journal-title":"Computation"},{"key":"60972_CR74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","volume":"578","author":"M Gerstung","year":"2020","unstructured":"Gerstung, M. et al. The evolutionary history of 2658 cancers. Nature 578, 122\u2013128. https:\/\/doi.org\/10.1038\/s41586-019-1907-7 (2020).","journal-title":"Nature"},{"key":"60972_CR75","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41588-020-0675-5","volume":"52","author":"G Caravagna","year":"2020","unstructured":"Caravagna, G. et al. Subclonal reconstruction of tumors by using machine learning and population genetics. Nat. Genet. 52, 898\u2013907. https:\/\/doi.org\/10.1038\/s41588-020-0675-5 (2020).","journal-title":"Nat. Genet."},{"key":"60972_CR76","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli, M. L. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22, 3764\u20133773. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2477 (2016).","journal-title":"Clin. Cancer Res."},{"key":"60972_CR77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s43018-020-0027-5","volume":"1","author":"A Degasperi","year":"2020","unstructured":"Degasperi, A. et al. A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies. Nat. Cancer 1, 249\u2013263. https:\/\/doi.org\/10.1038\/s43018-020-0027-5 (2020).","journal-title":"Nat. Cancer"},{"key":"60972_CR78","doi-asserted-by":"publisher","first-page":"abl9283","DOI":"10.1126\/science.abl9283","volume":"376","author":"A Degasperi","year":"2022","unstructured":"Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science 376, abl9283. https:\/\/doi.org\/10.1126\/science.abl9283 (2022).","journal-title":"Science"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60972-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:22:14Z","timestamp":1791847334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60972-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60972-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C. was in the past a recipient of research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca, and Servier. F.M. is co-founder and director of Tailor Bio.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31934"}}